Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2001 1
2006 1
2008 1
2009 1
2010 3
2011 4
2012 3
2013 2
2014 2
2015 2
2016 2
2017 2
2018 6
2019 4
2020 12
2021 9
2022 7
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir.
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, Laverdure S, Highbarger H, Lallemand P, Huang ML, Jerome KR, Sampoleo R, Mills MG, Greninger AL, Juneja K, Porter D, Benson CA, Dempsey W, El Sahly HM, Focht C, Jilg N, Paules CI, Rapaka RR, Uyeki TM, Lane HC, Beigel J, Dodd LE; Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members. Singh K, et al. J Infect Dis. 2024 Apr 24:jiae198. doi: 10.1093/infdis/jiae198. Online ahead of print. J Infect Dis. 2024. PMID: 38657001
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
Assessing past versus present severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection: A survey of criteria for discontinuing precautions in asymptomatic patients testing positive on admission.
Gohil SK, De St Maurice A, Yokoe DS, Cohen SH, Torriani FJ, Grein JD, Robinson PA, Mabalot S, Park J, Pedrani P, Platt R, Huang SS. Gohil SK, et al. Among authors: grein jd. Infect Control Hosp Epidemiol. 2024 Feb;45(2):237-240. doi: 10.1017/ice.2023.147. Epub 2023 Sep 13. Infect Control Hosp Epidemiol. 2024. PMID: 37702088 Free PMC article.
Coronavirus disease 2019 (COVID-19) infection prevention practices that exceed Centers for Disease Control and Prevention (CDC) guidance: Balancing extra caution against impediments to care.
Gohil SK, Septimus E, Sands KE, Blanchard EJ, Moody J, de St Maurice A, Yokoe D, Kwon J, Grein J, Cohen S, Uslan D, Vasudev M, Mauricio A, Mabalot S, Coady MH, Sljivo S, Smith K, Carver B, Poland R, Perlin J, Platt R, Huang SS; Centers for Disease Control and Prevention Epicenters Program. Gohil SK, et al. Among authors: grein j. Infect Control Hosp Epidemiol. 2023 Dec;44(12):2074-2077. doi: 10.1017/ice.2023.89. Epub 2023 Jun 1. Infect Control Hosp Epidemiol. 2023. PMID: 37260365 Free PMC article.
Characterizing the relationship between coronavirus disease 2019 (COVID-19) and central-line-associated bloodstream infection (CLABSI) and assessing the impact of a nursing-focused CLABSI reduction intervention during the COVID-19 pandemic.
Ben-Aderet MA, Madhusudhan MS, Haroun P, Almario MJP, Raypon R, Fawcett S, Johnson J, Girard A, Griner T, Sheffield L, Grein JD. Ben-Aderet MA, et al. Among authors: grein jd. Infect Control Hosp Epidemiol. 2023 Jul;44(7):1108-1115. doi: 10.1017/ice.2022.203. Epub 2022 Aug 31. Infect Control Hosp Epidemiol. 2023. PMID: 36043349 Free PMC article.
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
Wolfe CR, Tomashek KM, Patterson TF, Gomez CA, Marconi VC, Jain MK, Yang OO, Paules CI, Palacios GMR, Grossberg R, Harkins MS, Mularski RA, Erdmann N, Sandkovsky U, Almasri E, Pineda JR, Dretler AW, de Castilla DL, Branche AR, Park PK, Mehta AK, Short WR, McLellan SLF, Kline S, Iovine NM, El Sahly HM, Doernberg SB, Oh MD, Huprikar N, Hohmann E, Kelley CF, Holodniy M, Kim ES, Sweeney DA, Finberg RW, Grimes KA, Maves RC, Ko ER, Engemann JJ, Taylor BS, Ponce PO, Larson L, Melendez DP, Seibert AM, Rouphael NG, Strebe J, Clark JL, Julian KG, de Leon AP, Cardoso A, de Bono S, Atmar RL, Ganesan A, Ferreira JL, Green M, Makowski M, Bonnett T, Beresnev T, Ghazaryan V, Dempsey W, Nayak SU, Dodd LE, Beigel JH, Kalil AC; ACTT-4 Study Group. Wolfe CR, et al. Lancet Respir Med. 2022 Sep;10(9):888-899. doi: 10.1016/S2213-2600(22)00088-1. Epub 2022 May 23. Lancet Respir Med. 2022. PMID: 35617986 Free PMC article. Clinical Trial.
58 results